United Kingdom (UK)
Recombinant monoclonal antibody to CEA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma EB-022.
UniProt Accession Number of Target Protein: P06731
Alternative Name(s) of Target: Carcinoembryonic antigen; Carcinoembryonic antigen-related cell adhesion molecule 5; CEACAM5; Cluster of Differentiation 66e; CD66e
Immunogen: This antibody was generated by immunising BALB/c mice. Splenocytes from immunised mice were obtained and fused with myeloma cells to generate a hybridoma.
Specificity: EB-022 was shown by ELISA to react specifically with CEA (CD66e), as opposed to the related CD66 family member CD66c (also known as NCA; unpublished data).
Application Notes: EB-022 was used in ELISAs against CEA (CD66e) and NCA (CD66c) to show specificity of binding (unpublished data).
Antibody first published in: PMID:
Western Blot using anti-CEA antibody EB-022 (Ab01003). Human colorectal carcinoma (0.01µg/ml) tissue lysate (35µg protein in RIPA buffer) was resolved on a SDS PAGE gel and blots were probed with the chimeric rabbit version of EB-022 (Ab01003-23.0) before detection using an anti-rabbit secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence.
Immunofluorescence staining of MCF7 cells with anti-CEA (Ab01003) EB-022 Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells stained with the chimeric rabbit IgG version of EB-022 (Ab01003-23.0) (1:1000 dilution) for 1h followed by Alexa Fluor® 488 secondary antibody (1:1500 dilution), showing nuclear staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab01003-23.0, DAPI, merged channels and an isotype control. The isotype control was anti-fluorescein antibody (Ab00102-23.0) followed by staining with Alexa Fluor® 488 secondary antibody.